MEA Cellular Health Screening Market

MEA Cellular Health Screening Market Size (2023 to 2028)

The cellular health screening market in the Middle East and Africa had a sluggish growth in recent years. The market size in MEA is to value USD 0.48 billion by 2028 from USD 0.31 billion in 2023, registering a CAGR of 8.85% from 2023 to 2028.

The rising importance of healthy life expectancy; rising government focus on preventive healthcare; increasing geriatric population and consequent growth in the need for cellular health screening; increasing research activities; growing the rising burden of chronic diseases, as well as the adoption of the direct-to-consumer method, are projected to drive the expansion of this market. Furthermore, the cellular health screening market in the MEA is further expected to grow due to cellular health screening in precision and personalized medicine. Again, the increased acceptance of telomere performance programs for leading a healthy life and initiatives and the government's focus on raising public awareness are favorably driving the market growth.

Additionally, the increasing investment by the government and non-government organizations for the development of healthcare infrastructure and to provide preventive healthcare facilities to the people in the region is expected to fuel the market growth. The growing population is most likely to contribute to the market growth. The senior population is more susceptible to various chronic diseases, resulting in cellular health screening. In addition, the rising adoption of the direct-to-consumer approach and the adoption of healthy life expectancy among the people in the region are expected to accelerate the market growth. Government and key market players are significantly investing in the research and development activities expected to provide lucrative growth opportunities for the market growth. 

The market is projected to rise as telomere performance programs become more widely adopted. In addition, other reasons such as an increase in chronic cases, increased research activities, increased relevance of healthy life expectancy, rising population aging, and increased usage of digital technology for testing will propel the cellular health screening market. It also provides information on muscle tone, mass, and cellular function, enhancing its use in routine health screenings. Over the forecast term, this is expected to fuel market expansion even further. Moreover, the technological advancement in the healthcare sector is supporting the market growth, as the technology helps in areas that need immediate support and enables professionals to develop an individualized plan to achieve effective results. 

However, the rising problems related to sample transportation, unfavorable reimbursement rules, and differences in the cost kits given by different organizations are projected to impede the market expansion. In addition, the market is likely to be restrained by a lack of information about healthy living practices in remote locations over the forecast period. 

This research report on the MEA cellular health screening market has been segmented and sub-segmented into the following categories:

By Test Panels Type:

• Single Test Panels               
  • Telomere Tests
  • Inflammation Tests
  • Oxidative Stress Tests
  • Heavy Metal Tests
• Multi-Test Panels  

By Sample Type:

• Blood Samples
• Other Samples

By Sample Collection Site:

• In-Office Sample Collection
• At-Home Sample Collection
• Other Sample Collection

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa are expected to have a moderate proportion of the market share in the cellular health screening market during the forecast period. The market growth is driven owing to the increasing prevalence of chronic diseases, the rising importance of healthy life expectancy, and the growing government's focuses on developing better healthcare infrastructure. In addition, due to the various institutes' research in the Middle East and Africa, the usage of telomere test kits in cellular health screening and other application areas has increased, which is likely to boost the cellular health screening market in the forecast period.

South Africa held the region's largest share, and it is projected to expand its growth during the forecast period. The market growth is expected to be fuelled by the growing population with associated diseases, improving healthcare sectors, and supportive government policies.

South Arabia and UAE are projected to grow at a promising pace during the forecast period. This is because of the growing geriatric population, rising awareness about healthy lifestyles, preventive healthcare, and increasing research and development activities. On the other hand, the growth is attributed to an increase in government measures for preventative healthcare. For example, the UAE government committed USD 10 million in research in 2018 to prevent diseases and promote better health choices. These measures are expected to drive the MEA cellular health screening market forward.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the MEA Cellular Health Diagnostics Market profiled in this report are Genova Diagnostics (U.S.), Quest Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), and Cleveland HeartLab, Inc. (U.S.).